1. First Case of HIV Seroconversion With Integrase Resistance Mutations on Long-Acting Cabotegravir for Prevention in Routine Care
- Author
-
Koss, Catherine A, Gandhi, Monica, Halvas, Elias K, Okochi, Hideaki, Chu, Carolyn, Glidden, David V, Gomez, Lisa Georgetti, Heaps, Amy L, Conroy, Amy A, Tran, Michael, Shetler, Cory, Hoeth, Dianna, Kuncze, Karen, Louie, Alexander, Garza, Hana Rivera, Mugoma, Erick Wafula, Penrose, Kerri J, Chohan, Bhavna H, Ayieko, James O, Mills, Anthony, Patel, Rupa R, Mellors, John W, and Parikh, Urvi M
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Genetics ,Sexually Transmitted Infections ,Women's Health ,Infectious Diseases ,HIV/AIDS ,Prevention ,Infection ,Good Health and Well Being ,breakthrough infection ,HIV prevention ,pharmacokinetics ,pre-exposure prophylaxis ,resistance ,Clinical sciences ,Medical microbiology - Abstract
BackgroundLong-acting cabotegravir (CAB-LA) is highly effective for HIV prevention, but delayed HIV diagnoses and integrase strand transfer inhibitor (INSTI) resistance were observed in trials. We report the first case in routine clinical care of HIV infection on CAB-LA with INSTI resistance.MethodsThe SeroPrEP study enrolls individuals in the United States who acquire HIV on pre-exposure prophylaxis modalities to assess diagnostics, antiretroviral (ARV) drug levels, resistance, and treatment outcomes. Resistance mutations in full-length HIV-1 integrase were identified by single-genome sequencing (SGS). Cabotegravir concentrations in plasma and hair segments were measured by liquid chromatography-tandem mass spectrometry.ResultsA 23-year-old gender-nonbinary person, male at birth, restarted CAB-LA 6 months after discontinuation due to losing insurance. Prior to restart, HIV-1 RNA was not detected, but 20 days elapsed before CAB-LA injection. After the second CAB-LA injection, HIV antigen/antibody returned reactive (HIV-1 RNA 451 copies/mL). SGS of plasma HIV-1 RNA identified INSTI mutation Q148R in 2/24 sequences 2 days postdiagnosis; commercial genotype failed amplification. Cabotegravir hair concentration was 0.190 ng/mg 2 weeks prediagnosis; plasma cabotegravir was high (3.37 μg/mL; ∼20× PA-IC90) 14 days postdiagnosis. Viral suppression was maintained for 6 months on darunavir/cobicistat/emtricitabine/tenofovir alafenamide, then switched to doravirine + emtricitabine/tenofovir alafenamide due to nausea.ConclusionsIn this first case of HIV infection on CAB-LA with INSTI resistance in routine care, cabotegravir resistance was detected only with a sensitive research assay. Accelerated pathways to minimize time between HIV testing and CAB-LA initiation are needed to optimize acute HIV detection and mitigate resistance risk. Sustained product access regardless of insurance is imperative to reduce HIV infections on CAB-LA.
- Published
- 2024